Oruka Therapeutics Shares Surge 45% on Psoriasis Trial

Oruka Therapeutics shares jumped 45% after reporting positive Phase 2a EVERLAST‑A trial results for psoriasis drug ORKA‑001.
Primary endpoint met with 63.5% of patients achieving PASI 100 and IGA 0 at Week 16, indicating complete skin clearance.
Secondary endpoints showed 83% PASI 90 and 84% IGA 0/1 responses; placebo group had only one responder among 21.
Safety profile was favorable with no serious TEAEs, overall adverse events 51% vs 57% placebo, URTI most common.